Literature DB >> 5485143

Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive blockade of adrenoceptors.

R Charlier.   

Abstract

1. The cardiac actions of amiodarone, a benzofuran derivative used in the treatment of angina pectoris, have been compared with those of (+/-)-propranolol in anaesthetized dogs.2. After three successive intravenous injections of propranolol, 0.5 mg/kg, had reduced the heart rate by 25%, a fourth dose had no further negative chronotropic action, but amiodarone, 10 mg/kg intravenously, at this point reduced the heart rate by 23%.3. Amiodarone, 10 mg/kg intravenously, reduced, but did not abolish, cardiac responses to isoprenaline, 2 mug/kg intravenously. Subsequent successive injections of 10 mg/kg of amiodarone did not further block the responses to isoprenaline, but propranolol, 1 mg/kg intravenously, abolished them.4. Amiodarone reduced cardiac chronotropic and inotropic responses to glucagon, which were not affected by propranolol.5. Cardiac output was increased 5 min after amiodarone, 10 mg/kg intravenously, but at 10 min and thereafter it did not differ from control values. Propranolol, 1 mg/kg intravenously, reduced cardiac output by 17% at 5 min, and by 30% after 30 min.6. From this and other evidence which is discussed, it is concluded that the cardiac actions of amiodarone are not produced by competitive blockade of beta-adrenoceptors.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5485143      PMCID: PMC1702729          DOI: 10.1111/j.1476-5381.1970.tb09892.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

1.  Cardiac actions of glucagon.

Authors:  B R Lucchesi
Journal:  Circ Res       Date:  1968-06       Impact factor: 17.367

2.  Evaluation of sympathetic beta-receptor blockade by recording the rate of ventricular pressure rise in cats.

Authors:  B G Benfey; K Greeff; E Heeg
Journal:  Br J Pharmacol Chemother       Date:  1967-05

3.  The pharmacology of beta sympathetic blockade.

Authors:  R G Shanks
Journal:  Am J Cardiol       Date:  1966-09       Impact factor: 2.778

4.  The effect of lipolytic hormones and theophylline on heat production in brown adipose tissue in vivo.

Authors:  F Cockburn; D Hull; I Walton
Journal:  Br J Pharmacol Chemother       Date:  1967-11

5.  [Studies of the benzofuran series. XXV. Hemodynamic effects of amiodarone in the dog].

Authors:  R Charlier; A Baudine; F Chaillet; G Deltour
Journal:  Acta Cardiol       Date:  1967       Impact factor: 1.718

6.  Glucagon. Its enhancement of cardiac performance in the cat and dog and persistence of its inotropic action despite beta-receptor blockade with propranolol.

Authors:  G Glick; W W Parmley; A S Wechsler; E H Sonnenblick
Journal:  Circ Res       Date:  1968-06       Impact factor: 17.367

7.  Effect of beta adrenergic blockade on the cardiovascular dynamics.

Authors:  J Nakano; T Kusakari
Journal:  Am J Physiol       Date:  1966-04

8.  Effect of propranolol on systemic and coronary hemodynamics at rest and during simulated exercise.

Authors:  D H McKenna; R J Corliss; S Sialer; W C Zarnstorff; C W Crumpton; G G Rowe
Journal:  Circ Res       Date:  1966-09       Impact factor: 17.367

9.  Hemodynamic changes after beta adrenergic blockade.

Authors:  E Sowton; J Hamer
Journal:  Am J Cardiol       Date:  1966-09       Impact factor: 2.778

10.  [Studies in the series of benzofurans. XXIX. Effect of amiodarone on the metabolism of the heart in the dog].

Authors:  J Broekhuysen; G Deltour; M Ghislain; M Delbruyère
Journal:  Biochem Pharmacol       Date:  1967-11       Impact factor: 5.858

View more
  29 in total

1.  Pharmacological cardioversion of recent onset atrial fibrillation with intravenous amiodarone in patients receiving long-term amiodarone therapy: is it reasonable?

Authors:  Emmanuel M Kanoupakis; George E Kochiadakis; Emmanuel G Manios; Nikolaos E Igoumenidis; Hercules E Mavrakis; Panos E Vardas
Journal:  J Interv Card Electrophysiol       Date:  2003-02       Impact factor: 1.900

2.  Continuous spinal anaesthesia for abdominal surgery in a patient receiving amiodarone.

Authors:  D J Kopacz
Journal:  Can J Anaesth       Date:  1991-04       Impact factor: 5.063

3.  Hemodynamic effects of amiodarone during acute and chronic treatment in patients with recurrent sustained ventricular tachycardia.

Authors:  M Manz; W Jung; B Lüderitz
Journal:  Clin Investig       Date:  1992-05

Review 4.  Antiarrhythmic drug classifications. A critical appraisal of their history, present status, and clinical relevance.

Authors:  S Nattel
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

Review 5.  Recent advances in understanding the pharmacology of amiodarone.

Authors:  S Nattel; M Talajic
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

6.  Haemodynamic effects of short term intravenous amiodarone for hypertrophic cardiomyopathy.

Authors:  A Branzi; C Rapezzi; P M Benenati; G Binetti; G Piovaccari; M Bacchi; R Roncuzzi; R Zannoli; B Magnani
Journal:  Br Heart J       Date:  1988-04

7.  Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the beta-adrenoceptor and adenylate cyclase in rat heart.

Authors:  P Chatelain; L Meysmans; J R Mattéazzi; P Beaufort; M Clinet
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

Review 8.  Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia.

Authors:  Hugo Van Herendael; Paul Dorian
Journal:  Vasc Health Risk Manag       Date:  2010-08-09

9.  Acute effects of amiodarone upon the canine sinus node and atrioventricular junctional region.

Authors:  H O Gloor; F Urthaler; T N James
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

10.  Effects of amiodarone and thyroid dysfunction on myocardial calcium, serum calcium and thyroid hormones in the rat.

Authors:  M D Gammage; J A Franklyn; S D Logan
Journal:  Br J Pharmacol       Date:  1987-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.